Your browser doesn't support javascript.
loading
Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism.
Molinet-Dronda, Francisco; Blesa, Javier; Del Rey, Natalia López-González; Juri, Carlos; Collantes, María; Pineda-Pardo, Jose A; Trigo-Damas, Inés; Iglesias, Elena; Hernández, Ledia F; Rodríguez-Rojas, Rafael; Gago, Belén; Ecay, Margarita; Prieto, Elena; García-Cabezas, Miguel Á; Cavada, Carmen; Rodríguez-Oroz, María C; Peñuelas, Iván; Obeso, José A.
Afiliação
  • Molinet-Dronda F; Movement Disorders Laboratory, Neurosciences Area, CIMA, University of Navarra, Pamplona, Spain; Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Blesa J; Movement Disorders Laboratory, Neurosciences Area, CIMA, University of Navarra, Pamplona, Spain; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain; HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM H
  • Del Rey NL; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain; HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain; PhD Program in Neuroscience, Autónoma de Madrid University-Cajal Instit
  • Juri C; Movement Disorders Laboratory, Neurosciences Area, CIMA, University of Navarra, Pamplona, Spain; Department of Neurology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Collantes M; Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, IdiSNA, Pamplona, Spain; Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, Spain.
  • Pineda-Pardo JA; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain; HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.
  • Trigo-Damas I; Movement Disorders Laboratory, Neurosciences Area, CIMA, University of Navarra, Pamplona, Spain; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain; HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM H
  • Iglesias E; Movement Disorders Laboratory, Neurosciences Area, CIMA, University of Navarra, Pamplona, Spain.
  • Hernández LF; Movement Disorders Laboratory, Neurosciences Area, CIMA, University of Navarra, Pamplona, Spain; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain; HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM H
  • Rodríguez-Rojas R; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain; HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.
  • Gago B; Movement Disorders Laboratory, Neurosciences Area, CIMA, University of Navarra, Pamplona, Spain; Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Universidad de Málaga, Málaga, Spain.
  • Ecay M; Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, IdiSNA, Pamplona, Spain; Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, Spain.
  • Prieto E; Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, Spain; Medical Physics, Clínica Universidad de Navarra, Pamplona, Spain.
  • García-Cabezas MÁ; PhD Program in Neuroscience, Autónoma de Madrid University-Cajal Institute, Madrid 28029, Spain; Department of Anatomy, Histology and Neuroscience, School of Medicine, Autónoma de Madrid University, Madrid, Spain.
  • Cavada C; PhD Program in Neuroscience, Autónoma de Madrid University-Cajal Institute, Madrid 28029, Spain; Department of Anatomy, Histology and Neuroscience, School of Medicine, Autónoma de Madrid University, Madrid, Spain.
  • Rodríguez-Oroz MC; Movement Disorders Laboratory, Neurosciences Area, CIMA, University of Navarra, Pamplona, Spain.
  • Peñuelas I; Translational Molecular Imaging Unit (UNIMTRA), Clínica Universidad de Navarra, IdiSNA, Pamplona, Spain; Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, Spain.
  • Obeso JA; Movement Disorders Laboratory, Neurosciences Area, CIMA, University of Navarra, Pamplona, Spain; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain; HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM H
Neurobiol Dis ; 167: 105669, 2022 06 01.
Article em En | MEDLINE | ID: mdl-35219857
ABSTRACT
Dopaminergic denervation in patients with Parkinson's disease is associated with changes in brain metabolism. Cerebral in-vivo mapping of glucose metabolism has been studied in severe stable parkinsonian monkeys, but data on brain metabolic changes in early stages of dopaminergic depletion of this model is lacking. Here, we report cerebral metabolic changes associated with progressive nigrostriatal lesion in the pre-symptomatic and symptomatic stages of the progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model of Parkinson's Disease. Monkeys (Macaca fascicularis) received MPTP injections biweekly to induce progressive grades of dopamine depletion. Monkeys were sorted according to motor scale assessments in control, asymptomatic, recovered, mild, and severe parkinsonian groups. Dopaminergic depletion in the striatum and cerebral metabolic patterns across groups were studied in vivo by positron emission tomography (PET) using monoaminergic ([11C]-dihydrotetrabenazine; 11C-DTBZ) and metabolic (2-[18F]-fluoro-2-deoxy-d-glucose; 18F-FDG) radiotracers. 11C-DTBZ-PET analysis showed progressive decrease of binding potential values in the striatum of monkeys throughout MPTP administration and the development of parkinsonian signs. 18F-FDG analysis in asymptomatic and recovered animals showed significant hypometabolism in temporal and parietal areas of the cerebral cortex in association with moderate dopaminergic nigrostriatal depletion. Cortical hypometabolism extended to involve a larger area in mild parkinsonian monkeys, which also exhibited hypermetabolism in the globus pallidum pars interna and cerebellum. In severe parkinsonian monkeys, cortical hypometabolism extended further to lateral-frontal cortices and hypermetabolism also ensued in the thalamus and cerebellum. Unbiased histological quantification of neurons in Brodmann's area 7 in the parietal cortex did not reveal neuron loss in parkinsonian monkeys versus controls. Early dopaminergic nigrostriatal depletion is associated with cortical, mainly temporo-parietal hypometabolism unrelated to neuron loss. These findings, together with recent evidence from Parkinson's Disease patients, suggest that early cortical hypometabolism may be associated and driven by subcortical changes that need to be evaluated appropriately. Altogether, these findings could be relevant when potential disease modifying therapies become available.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Parkinsonianos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Parkinsonianos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article